SEER - Momentum Play?Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Disclaimer: This content is for informational purposes only and is not intended as financial advice.
Investment Overview (Dated 04/23/24):
Relative Volume: 3.09
Shares Float: 46.3 million
Market Activity:
Recent activities include a significant block buy and the acquisition of a passive stake, indicating potential investor interest.
Key Technical Levels:
Resistance Levels: Monitor key resistance at $2.20 and $3.00. A break above these levels may suggest a potential upward movement. Consider taking partial profits at these thresholds to realize gains.
Trading Strategy:
Take Profit (TP): Set a profit target around $4.00 to maximize returns.
Stop Loss (SL): Maintain a stop loss strategy below $1.60 to minimize potential losses.
Chart Analysis: Please refer to the accompanying chart for a detailed visual analysis of price actions and trend lines.
Trading Caution: Engage in trading with careful consideration of market conditions and personal risk tolerance. It is advised to conduct thorough research or consult a financial advisor before making any investment decisions.
SEER trade ideas
Avoid this crapSeers Inc received a bumper listing valuing it at $3.3 billion for a revenue of less than $1 million.
It is claimed that company has a breakthrough for studying proteins and for diagnostics.
Seers Inc received a bumper listing valuing it at $3.3 billion for revenue of less than $1 million. It is claimed that the company has a breakthrough for studying proteins and for diagnostics.
Let's break it down.
The product has the following elements in it:
1) It claims to create a 'Proteograph' of proteins.
It is done by breaking down protein into peptides.
The above process is widely used in research and protein studies. This is not a new thing, nor propitiatory.
2) Peptides are run through a Mass-spectrometer (mass-spec).
Mass-specs are widely used, and so far, the company is not into making it. They rely on users for the mass-spec.
3) Deep profiling the data with proteigraph.
Proteigraph-based deep proteomic profiling is an oversold concept of deep-profiling, ML-enabled data analysis, AI-based prediction.
Though the software suite is new, it is not unique. Researchers in the field analyze the data by writing python/R scripts for deep data analysis, and there are plenty of free codes available in the research journal to use. Though not a breakthrough, the software package is new.
The risk is mass-spec manufacturers have packages for several applications and data analysis. This can be easily developed by the manufacturers and independent package sellers.
4) Use of nano-particle for 'Protein-Corona'
Prof. Omid (Co-founder) and Prof. Langer (Co-founder), published their findings on 'protein-corona' between 2015-17. The latest scientific publication came out this summer, elaborating the concept and demonstrating the use of all the four components of the product.
'Protein-corona' is created by smartly using nano-particles (no-proprietary) to capture proteins with different charges.
The company reported a revenue of less than $1 million in the last two yrs of operation. Despite claiming to have research use, co-founders associated with the Harvard-MIT eco-system, and connections in the bay-area research community could not manage a revenue of more than $1 million! Does this breakthrough deserve a $3.3 billion listing valuation??
This is an elaborate marketing show pulled-off by the co-founders and gullible investors buying into it.
Avoid junk. Happy investing.